Vishnu Amble的动态

2024 for the UK Biotech industry is going surprisingly well! We have already surpassed the total amount of finance that was raised in the whole of 2023! There's been a significant rise in VC funding, with ￡564 million raised in Q2 alone. Some great stories from here include Pheon Therapeutics securing ￡94 million Series B & Amber Therapeutics raising ￡79 million! Public financing (other than IPOs) has had a marked increase, with ￡577 million raised. We still had no IPOs recorded in the first half 2024... highlighting a much more cautious approach when it comes to new market launch. Globally, the UK’s fundraising efforts have remained competitive compared to significant biotech hubs in the US and Europe. I'm excited to see what our industry achieves for the final 4 months of 2024! #biotech #lifesciences #investment #fundraising

Flagship Pioneering, one of the largest firms investing in and creating new biotech companies, said Wednesday that it has raised $3.6 billion in new funding. Flagship’s fundraising is a high point in the broader biotech VC ecosystem, which has faced headwinds, thanks to the biotech market downturn and larger economic shifts in the U.S. What do you think about the future of life science VC fundraising? Will other firms be able to raise mega-funds like Flagship? #biotech #biopharma #lifesciences #fundraising #VC #privateequity #venturestrategies #venturefundraising

Two mega-funds lately raised $3.630b and want to enable the next stage of biotech development. And these are ARCH Venture Partners and Frazier Life Sciences. Arch closed a fund with $3 billion in cash ready to be deployed in early to medium stage companies that their future holds strong drug blockbuster promise. They claimed they have the patience to wait even for decades down the line for the return to come for those ventures that worth the risk. Some of the companies already benefiting from Arch's fund are: - Arsenal Biosciences, Inc. - Mirador Therapeutics - Xaira Therapeutics - Metsera I assume their due diligence team is great enough to discover the "unseen" best to invest! And Frazier Life Sciences (FLS) has sourced a further $630 million for its fund. The focus will be on small and mid-cap biotechs. Around $1.7 billion have been raised since the fund was set up three years ago. While the fund is aiming to fund "turbulent" cash-starving small to medium size biotechs that have good science to justify the investment capital, FLS wants to jump in and fund - if after due diligence makes sense - later stage companies that need the money to propel their clinical stages. Together with J.P Morgan's Life Science fund (+$500m), now FLS and Arch are showing us some signs of re-emerging confidence into deployment of investment capital within the biotech industry.

Sands Capital, ?? ?????????????? ?????????????? ???????? ?????????? ???? ??????????????????, ????????????????, ?????? ???????????????? ?????????????????? ?????? ???????????????????? ?????????? ???? ?? ?????? $?????? ?????????????? ???????? ?????????????? ????????. With this latest raise, Sands Capital's total committed capital for life science investments now stands at $??.?? ?????????????? ???????????? ?????????? ?????????????????? ??????????. Overall, the firm manages more than $???? ?????????????? in private and public investments, with over $5 billion allocated to healthcare and life science sectors. While the firm did not disclose specific therapeutic focuses, it mentioned a priority on "private therapeutics" among other life science ventures. Sands has already participated in significant funding rounds this year, including BioAge Labs' $?????? ?????????????? ???????????? ?? round, showcasing its commitment to supporting innovative biotech endeavors. https://lnkd.in/diQChaaE #LifeScienceInvesting #BiotechFunding #HealthcareVentures #VCInvestments #BiotechInnovation

J.P. Morgan Private Capital has recently closed an inaugural life sciences fund of more than $500 million, which will go towards a wide range of private biotechs in all stages of development. Learn more from Fierce Biotech: #biotech | #fundraising | #capital

Seroba., a leading venture capital firm based in Dublin and specializing in life sciences, has successfully closed its fourth fund, Seroba Fund IV, with a total capital of €123 million. This new fund is set to make a significant impact in the life sciences sector, with plans to invest in up to 12 companies. Already, investments have been made in five promising companies, including Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics, and ARTICA Therapeutics , each dedicated to addressing critical medical needs. ???????? ?????? ?????????????? ?? https://lnkd.in/ddAgr4aR Catello Somma Bruno Montanari Maud Lazare Daniel O'Mahony Alan O'Connell Vicky La Touche-Price Jennifer McMahon Andrew Duignan FCA, AITI, QFA, BA (Hons) Sophie Hughes, PhD #venturecapital #lifescience #startups #founders #privateequity #investments #investmentfund #vc #investors

US #biotech #fundraising boom ends 2-year deal drought - today from Nicholas Megaw in the Financial Times ???? 3 #highlights ?? 1?? Drug developers raised $6.2bn in equity capital markets in January, according to data from Jeffries. That marked the largest total since February 2021, the same month that the most popular tracker of biotech stocks hit its all-time high. Sharp turnaround after the last 2 years. 2?? Fundraising has been encouraged by a rebound in stock prices, expectations that the Federal Reserve will soon start cutting interest rates, and a boom in mergers and acquisitions activity in the sector. 3?? The SPDR biotech ETF has since rebounded about 40 per cent since late October as investors bet that interest rates had peaked. #innovation #fundraising #privatemoney #publicmarkets #biotech https://lnkd.in/gkki579W

Atlas Venture, which counts 56 portfolio biotechs, is looking at keeping its 14th fund the same size as its 13th: $450 million. The firm had progressively?increased the size of its last few funds but is looking at a "disciplined" new fund, according to an annual review presentation posted on Monday, Nov. 18. Atlas raised $280 million for its 10th fund in 2015, $350 million in 2017, $400 million in 2020 and then $450 million for its 13th batch in 2022. Atlas has been quite active in 2024. It has disclosed investments in about a dozen private biotechs, according to the presentation. One of those, obesity biotech Kailera, secured one of the industry’s largest private funding rounds of this year. About 10 more have been made in stealth mode, according to the presentation. #biotech #biotechventurecapital #lifesciencesvc #biotechvc #atlasventure

Highly recommended for both issuers and investors.

The first VC Fundraising Workshop organized by KHAN Technology Transfer Fund I and wings4innovation GmbH took place in Vienna this week. The aim of the workshop was for our portfolio companies CasInvent Pharma, Cutanos GmbH, KinSea Lead Discovery AS, and RIANA Therapeutics to share their experiences in raising venture capital and to learn from each other's best practices. The discussions were very constructive and I think everyone took away something for themselves and their company for the current financing rounds and perhaps already for the upcoming investor meetings at the BIO Spring conference. Good luck to all participants! Don't forget: Have your investment case clear, be selective in choosing the right investors and do your homework before you approach an investor!??? #venturecapital #seedfunding #seedcapital #fundraising